EA032344B1 - Применение готового для использования состава, содержащего раствор эсмолол гидрохлорида, и способ лечения - Google Patents
Применение готового для использования состава, содержащего раствор эсмолол гидрохлорида, и способ лечения Download PDFInfo
- Publication number
- EA032344B1 EA032344B1 EA201491841A EA201491841A EA032344B1 EA 032344 B1 EA032344 B1 EA 032344B1 EA 201491841 A EA201491841 A EA 201491841A EA 201491841 A EA201491841 A EA 201491841A EA 032344 B1 EA032344 B1 EA 032344B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- solution
- ready
- intravenous
- patient
- tachycardia
- Prior art date
Links
- VZTMYLWJKCAXMZ-UHFFFAOYSA-N 2-[(2-chloroquinazolin-4-yl)amino]ethanol Chemical compound C1=CC=C2C(NCCO)=NC(Cl)=NC2=C1 VZTMYLWJKCAXMZ-UHFFFAOYSA-N 0.000 title claims abstract description 33
- 229960001015 esmolol hydrochloride Drugs 0.000 title claims abstract description 33
- 238000011282 treatment Methods 0.000 title claims abstract description 11
- 238000000034 method Methods 0.000 title claims abstract description 10
- 239000000203 mixture Substances 0.000 title claims description 34
- 238000009472 formulation Methods 0.000 title description 2
- 238000001990 intravenous administration Methods 0.000 claims abstract description 68
- 239000008176 lyophilized powder Substances 0.000 claims abstract description 22
- 239000002904 solvent Substances 0.000 claims abstract description 20
- 208000001871 Tachycardia Diseases 0.000 claims abstract description 17
- 230000006794 tachycardia Effects 0.000 claims abstract description 17
- 239000000872 buffer Substances 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 10
- 239000000243 solution Substances 0.000 claims description 120
- 238000001802 infusion Methods 0.000 claims description 25
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 17
- 239000008103 glucose Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 229960003745 esmolol Drugs 0.000 claims description 12
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 12
- 239000007924 injection Substances 0.000 claims description 12
- 239000008215 water for injection Substances 0.000 claims description 11
- 238000012423 maintenance Methods 0.000 claims description 9
- 239000002504 physiological saline solution Substances 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 6
- 210000003462 vein Anatomy 0.000 claims description 6
- 230000007794 irritation Effects 0.000 claims description 5
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 3
- 206010003662 Atrial flutter Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 208000001953 Hypotension Diseases 0.000 claims description 3
- 208000007888 Sinus Tachycardia Diseases 0.000 claims description 3
- 206010040893 Skin necrosis Diseases 0.000 claims description 3
- 208000003734 Supraventricular Tachycardia Diseases 0.000 claims description 3
- 210000000709 aorta Anatomy 0.000 claims description 3
- 238000002224 dissection Methods 0.000 claims description 3
- 210000005069 ears Anatomy 0.000 claims description 3
- 230000036543 hypotension Effects 0.000 claims description 3
- 230000002980 postoperative effect Effects 0.000 claims description 3
- 206010000489 Acidosis hyperchloraemic Diseases 0.000 claims description 2
- 206010016803 Fluid overload Diseases 0.000 claims description 2
- 208000029422 Hypernatremia Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 230000036772 blood pressure Effects 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 230000001020 rhythmical effect Effects 0.000 claims description 2
- 206010047302 ventricular tachycardia Diseases 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 239000006172 buffering agent Substances 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 239000000644 isotonic solution Substances 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 208000001297 phlebitis Diseases 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 201000005060 thrombophlebitis Diseases 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010060708 Induration Diseases 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 210000002048 axillary vein Anatomy 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000085 chronic toxic effect Toxicity 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229920002457 flexible plastic Polymers 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000008012 organic excipient Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008063 pharmaceutical solvent Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000003421 short acting drug Substances 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000001321 subclavian vein Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12167443 | 2012-05-10 | ||
| PCT/EP2013/059594 WO2013167657A1 (en) | 2012-05-10 | 2013-05-08 | Parenteral esmolol formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201491841A1 EA201491841A1 (ru) | 2015-02-27 |
| EA032344B1 true EA032344B1 (ru) | 2019-05-31 |
Family
ID=48407551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201491841A EA032344B1 (ru) | 2012-05-10 | 2013-05-08 | Применение готового для использования состава, содержащего раствор эсмолол гидрохлорида, и способ лечения |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US20150087704A1 (enExample) |
| EP (1) | EP2846776B1 (enExample) |
| JP (1) | JP6220383B2 (enExample) |
| CN (1) | CN104379134A (enExample) |
| AU (1) | AU2013258031B2 (enExample) |
| BR (1) | BR112014027870B1 (enExample) |
| CA (1) | CA2872953C (enExample) |
| CL (1) | CL2014003028A1 (enExample) |
| DK (1) | DK2846776T3 (enExample) |
| EA (1) | EA032344B1 (enExample) |
| ES (1) | ES2794093T3 (enExample) |
| HR (1) | HRP20200897T1 (enExample) |
| HU (1) | HUE049314T2 (enExample) |
| IL (1) | IL235497A0 (enExample) |
| LT (1) | LT2846776T (enExample) |
| MA (1) | MA37500B1 (enExample) |
| MX (1) | MX374771B (enExample) |
| MY (1) | MY173900A (enExample) |
| NZ (1) | NZ701429A (enExample) |
| PH (1) | PH12014502494B1 (enExample) |
| PL (1) | PL2846776T3 (enExample) |
| PT (1) | PT2846776T (enExample) |
| SI (1) | SI2846776T1 (enExample) |
| TN (1) | TN2014000464A1 (enExample) |
| UA (1) | UA115333C2 (enExample) |
| WO (1) | WO2013167657A1 (enExample) |
| ZA (1) | ZA201408149B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019122157A1 (en) * | 2017-12-21 | 2019-06-27 | Ipsol Ag | A lyophilisate comprising esmolol and adenosine for use in cardioplegia |
| CN111848420A (zh) * | 2020-07-22 | 2020-10-30 | 杭州煌森生物科技有限公司 | 一种盐酸艾司洛尔的新晶型及制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6310094B1 (en) * | 2001-01-12 | 2001-10-30 | Baxter International Inc. | Ready-to-use esmolol solution |
| TWI277414B (en) | 2001-01-12 | 2007-04-01 | Baxter Int | Esmolol formulation |
| SE0401842D0 (sv) * | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| WO2007026771A1 (ja) * | 2005-08-31 | 2007-03-08 | Ono Pharmaceutical Co., Ltd. | 点滴用注射剤 |
| US20080293814A1 (en) | 2007-05-22 | 2008-11-27 | Deepak Tiwari | Concentrate esmolol |
| JP5623288B2 (ja) | 2007-12-21 | 2014-11-12 | エイオーピーオーファン ファーマスーティカルズ アクチエンゲゼルシャフトＡＯＰ Ｏｒｐｈａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 医薬組成物 |
| CN102106846A (zh) * | 2009-12-23 | 2011-06-29 | 南京海辰药业有限公司 | 左旋盐酸艾司洛尔药物组合物及其制备方法 |
-
2013
- 2013-05-08 JP JP2015510815A patent/JP6220383B2/ja active Active
- 2013-05-08 CN CN201380028099.XA patent/CN104379134A/zh active Pending
- 2013-05-08 SI SI201331732T patent/SI2846776T1/sl unknown
- 2013-05-08 HR HRP20200897TT patent/HRP20200897T1/hr unknown
- 2013-05-08 MX MX2014013556A patent/MX374771B/es active IP Right Grant
- 2013-05-08 WO PCT/EP2013/059594 patent/WO2013167657A1/en not_active Ceased
- 2013-05-08 LT LTEP13721740.2T patent/LT2846776T/lt unknown
- 2013-05-08 CA CA2872953A patent/CA2872953C/en active Active
- 2013-05-08 EA EA201491841A patent/EA032344B1/ru not_active IP Right Cessation
- 2013-05-08 UA UAA201413014A patent/UA115333C2/uk unknown
- 2013-05-08 DK DK13721740.2T patent/DK2846776T3/da active
- 2013-05-08 PT PT137217402T patent/PT2846776T/pt unknown
- 2013-05-08 US US14/398,312 patent/US20150087704A1/en not_active Abandoned
- 2013-05-08 NZ NZ701429A patent/NZ701429A/en unknown
- 2013-05-08 EP EP13721740.2A patent/EP2846776B1/en active Active
- 2013-05-08 PL PL13721740T patent/PL2846776T3/pl unknown
- 2013-05-08 ES ES13721740T patent/ES2794093T3/es active Active
- 2013-05-08 AU AU2013258031A patent/AU2013258031B2/en active Active
- 2013-05-08 HU HUE13721740A patent/HUE049314T2/hu unknown
- 2013-05-08 BR BR112014027870-9A patent/BR112014027870B1/pt active IP Right Grant
- 2013-05-08 MY MYPI2014703249A patent/MY173900A/en unknown
-
2014
- 2014-10-31 TN TN2014000464A patent/TN2014000464A1/fr unknown
- 2014-11-04 IL IL235497A patent/IL235497A0/en active IP Right Grant
- 2014-11-05 MA MA37500A patent/MA37500B1/fr unknown
- 2014-11-07 CL CL2014003028A patent/CL2014003028A1/es unknown
- 2014-11-07 PH PH12014502494A patent/PH12014502494B1/en unknown
- 2014-11-07 ZA ZA2014/08149A patent/ZA201408149B/en unknown
-
2017
- 2017-07-28 US US15/663,645 patent/US20170326095A1/en not_active Abandoned
-
2022
- 2022-01-24 US US17/582,945 patent/US11963940B2/en active Active
Non-Patent Citations (4)
| Title |
|---|
| Anonymous: "ESMOCARD LYO 2500 mg powder for concentrate for solution for infusion", CGB-MEB (College ter Beoordeling van Geneesmiddelen-Medicines Evaluation Board), 7 September 2010 (2010-09-07), pages 1-13, XP002683621, Retrieved from the Internet: URL:http://db.cbg-meb.nl/mri/spc/nlh-0779-003.pdf [retrieved on 2012-09-17] the whole document, page 1, lines 34-36, page 11, paragraph 6.1 List of excipients, page 12, paragraph INSTRUCTIONS FOR USE * |
| Anonymous: "PACKAGE LEAFLET: INFORMATION FOR THE USER: ESMOCARD LYO", CGB-MEB (College ter Beoordeling van Geneesmiddelen-Medicines Evaluation Board), 9 November 2010 (2010-11-09), pages 1-8, XP002683622, Retrieved from the Internet: URL:http://db.cbg-meb.nl/mri/pil/nlh-0779-003.pdf [retrieved on 2012-09-12] the whole document * |
| Anonymous: "Product Name in the RMS: Esmocard Lyo", HMA, Health of Medicines Agencies 9 September 2010 (2010-09-09), 20 December 2011 (2011-12-20), pages 1-2, XP002683623, Retrieved from the Internet: URL:http://mri.medagencies.org/Human/Product/Details/2363 [retrieved on 2012-09-17] the whole document, page 2, paragraph Documents * |
| Hantzen Stevenson: "PUBLIC ASSESSMENT REPORT of the Medicines Evaluation Board in the Netherlands: Esmolol HCl LYO Orpha 2500 mg powder for concentrate solution for infusion", CGB-MEB (College ter Beoordeling van Geneesmiddelen-Medicines Evaluation Board), 4 January 2011 (2011-01-04), pages 1-9, XP002683620, Retrieved from the Internet: URL:http://db.cbg-meb.nl/mri/par/nlh-0779-003.pdf [retrieved on 2012-09-17] the whole document, page 5, lines 3-8 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5522877B2 (ja) | モキシフロキサシン／塩化ナトリウム製剤 | |
| JP6888091B2 (ja) | スルホニル尿素系薬の医薬組成物及びその調製方法 | |
| JP7409772B2 (ja) | ダントロレンを含む水性組成物 | |
| US20210106686A1 (en) | Formulations of bendamustine | |
| WO2007112675A1 (fr) | Protéine de fusion du récepteur du vegf et son utilisation | |
| JP2018531268A6 (ja) | ダントロレンを含む水性組成物 | |
| JP6159567B2 (ja) | 既製のゲムシタビン注入溶液 | |
| US20100136140A1 (en) | A use of hypertonic solution composition in manufacturing medicaments for promoting wound healing | |
| RU2286774C2 (ru) | Препарат эсмолола | |
| US11963940B2 (en) | Parenteral esmolol formulation | |
| US20210046025A1 (en) | Injection for Protecting Ischemic Myocardium and Preparation Method thereof | |
| ES2290575T3 (es) | Concentrados de soluciones de oxaliplatino. | |
| JP3720262B2 (ja) | 安定化したカルベジロール注射溶液 | |
| US12397005B2 (en) | Pharmaceutical compositions of torsemide and uses thereof | |
| JP6629850B2 (ja) | 汎用心停止液（変種） | |
| CN108354899A (zh) | 一种治疗或预防麻醉低血压的复方注射剂及其制备方法 | |
| CN102885766B (zh) | 一种右旋酮洛芬注射液及其制备方法 | |
| CN102266298A (zh) | 一种培美曲塞二钠的药物组合物 | |
| HK1204265B (en) | Parenteral esmolol formulation | |
| US20230057383A1 (en) | Composition and methods for prevention and treatment of vascular disorders, neurodegenerative disease and neuropathic disorders | |
| JP2002538119A (ja) | 血圧低下のためのレミフェンタニルの使用 | |
| WO2020025986A1 (en) | Injectable combination of diclofenac sodium and thiocolchicoside | |
| JPS62242622A (ja) | 虚血性脳血管障害治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KG TJ TM |